Contineum, J&J’s depression drug fails to meet mid-stage trial goal
Sept 15 (Reuters) – Contineum Therapeutics said on Monday an experimental depression drug it developed with Johnson & Johnson failed to meet the main goal of a mid-stage study. Here are the details: • The trial was testing the drug, JNJ-5120 or PIPE-307, in patients with major depressive disorder, o

























